Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Amolyt Pharma's headquarters in Écully, France

Michael Culler

Guillaume Ravel, PharmD, PhD, DABT

michel ovize

Héloïse Boullet

Laetitia Ouafki

Patrick Loustau

Caroline Robo (Fesquet)

Jeanine Nguy

Eva MARCON

Divya Gupta

The Clinical Management Team at Amolyt Pharma oversees the planning, execution, and management of clinical trials for their peptide-based therapies targeting rare endocrine and metabolic disorders. This includes coordinating with cross-functional teams to ensure the accurate collection and analysis of clinical data, maintaining compliance with regulatory requirements, and driving the overall strategic direction of clinical projects. Their efforts facilitate the advancement of drug candidates like AZP-3601 and AZP-3404 from research phases to potential market approval.

Clinical Management Team

The Leadership Team at Amolyt Pharma is responsible for setting the strategic vision, overseeing financial planning, directing scientific research, and managing business development to advance the company's mission of developing peptides for rare endocrine and metabolic disorders.

Leadership Team

The CMC Team at Amolyt Pharma focuses on Chemistry, Manufacturing, and Controls for their peptide-based therapies. They are responsible for ensuring the development, production, and quality control of drug substances and products like AZP-3601 and AZP-3404, ensuring they meet regulatory standards and are safe and effective for treating rare endocrine and metabolic disorders.

CMC Team

The Finance Team at Amolyt Pharma manages the company's financial health, overseeing budgeting, financial planning, and analysis. They handle accounting, ensure regulatory compliance, and provide strategic insights to support the development of peptide treatments for rare endocrine and metabolic disorders.

Finance Team

The Medical Affairs and Development team at Amolyt Pharma spearheads the clinical advancement and medical strategy of peptide treatments for rare endocrine and metabolic disorders. They ensure that all preclinical and clinical data align with regulatory standards, engage with global medical communities to communicate scientific insights, and drive initiatives to optimize patient outcomes and treatment adoption.

Medical Affairs and Development

The Regulatory and Quality Management team at Amolyt Pharma ensures compliance with global regulatory standards and maintains the highest quality assurance for the development of peptide therapies. The team drives regulatory strategy, quality systems, and documentation to secure approvals and uphold the safety and efficacy of treatments such as AZP-3601 and AZP-3404.

��

Amolyt Pharma

Org chart

Teams

Clinical Management Team

Leadership Team

CMC Team

Finance Team

Medical Affairs and Development

Regulatory and Quality Management

Offices

��������

Amolyt Pharma

Org chart

Teams

Clinical Management Team

Leadership Team

CMC Team

Finance Team

Medical Affairs and Development

Regulatory and Quality Management

Offices

Related companies

��